BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
Olivier J Van NotAlfons J M van den EertweghJohn B HaanenRozemarijn S van RijnMaureen J B AartsFranchette W P J van den BerkmortelChristian U BlankMarye J Boers-SonderenJan Willem W B de GrootGeke A P HospersEllen KapiteijnManja BloemDjura PiersmaMarion Stevense-den BoerRik J VerheijdenAstrid A M van der VeldtMichel W J M WoutersWilleke A M BlokxKarlijn P M SuijkerbuijkPublished in: Cancer (2024)
This study confirms that patients benefit from rechallenge. Elevated LDH levels, symptomatic brain metastases, and discontinuing first BRAFi(/MEKi) treatment due to progression are associated with less benefit from rechallenge. A prolonged treatment interval is associated with more benefit from rechallenge.